Introduction {#S0001}
============

In February 2017, the World Health Organization (WHO) published a list of "critical" resistant bacterial species, including carbapenem-resistant *Pseudomonas aeruginosa, Acinetobacter baumannii*, and *Escherichia coli*. The same document urged the development of new, alternative treatments and/or new antimicrobials to reduce the number of deaths caused by multi-drug-resistant (MDR) bacteria[@CIT0001]

The antimicrobial peptide colistin was introduced in 1949 but in the 1980s it was withdrawn because of its nephrotoxicity and neurotoxicity. However, in the 2000s, clinicians again turned to colistin in an effort to treat infections caused by MDR Gram-negative bacteria[@CIT0002] Colistin is polycationic and interacts with negatively charged membrane components, including lipopolysaccharide (LPS), to disrupt cell membranes. Other activities contributing to colistin's bactericidal effect are ribosome binding, alterations of bacterial respiration, disturbances of the bacterial division, the induction of structural injuries, and the production of reactive oxygen species.[@CIT0003],[@CIT0004] Nevertheless, the precise mechanisms of action of colistin and other polymyxins are not yet fully understood.

Because the toxicity of colistin is dose-dependent,[@CIT0005] there is considerable interest in strategies that allow dose reductions while maintaining the therapeutic efficacy of the drug[@CIT0006] An additional consideration is the increasing frequency of colistin-resistant isolates. Among the resistance mechanisms identified thus far are modifications of LPS (*Pho*PQ and *Pmr*AB, a two-component regulatory system) and a transferable mechanism of resistance (*mcr*-1)[@CIT0007] The heterogeneous resistance (heteroresistance) of bacterial populations to colistin has also been described. However, a previous study suggested that the negative impact of colistin heteroresistance can be minimized by co-treatment with other antimicrobial agents[@CIT0008]

Synergism between colistin and other peptide molecules with a wide variety of antimicrobial activities has been explored. While colistin-carbapenem (β-lactams) is probably the best-studied combination,[@CIT0009]--[@CIT0011] synergies between colistin and quinolones, fosfomycin, and aminoglycosides have been reported as well[@CIT0012] Moreover, even though Gram-negatives are intrinsically resistant to linezolid and glycopeptides, their use in combination with colistin may be therapeutically promising. In fact, in vitro synergisms between colistin and linezolid against *A. baumannii* clinical strains[@CIT0013] and between colistin and glycopeptides in a *Galleria mellonella* model of infection[@CIT0014] were recently demonstrated. By disrupting the outer membrane to alter cytoplasmic membrane permeability, colistin allows both linezolid and glycopeptides to penetrate Gram-negative bacteria, which are otherwise impervious to these agents. A disturbance of the bacterial membrane may also underlie the observed synergies between colistin or colistin-like peptides and other, chemically unrelated antimicrobial agents.[@CIT0015] Thus, in this study we examined the role of colistin synergism with other antimicrobials with respect to: i) a reduction of the colistin dose and its impact on the drug's toxicity and ii) strategies allowing the avoidance of resistance development. Since the chloramphenicol resistance of MDR bacteria is mediated by the cellular efflux machinery, the focus of our study was the effect of colistin on cellular efflux pumps. Synergy between colistin and chloramphenicol was reported by Abdul Rahim et al[@CIT0016] Our results provide evidence of critical alterations in the efflux machinery of cells exposed to low concentrations of colistin and of the efficacy of other antimicrobials when administered in combination with colistin.

Materials and methods {#S0002}
=====================

Bacterial strains, culture conditions, and media {#S0002-S2001}
------------------------------------------------

The 24 clinical isolates used in this study differed in their clinical origins and included 7 strains of MDR *Pseudomonas aeruginosa*, 9 strains of MDR *Escherichia coli*, and 7 of MDR *Acinetobacter baumannii*. None of the strains were epidemiologically related. *Pseudomonas aeruginosa* ATCC 27853 and PAO1, *Escherichia coli* ATCC 25922, and *Acinetobacter baumannii* ATCC 17978 served as control strains. In addition, four strains of *Serratia marcescens* (two environmental and two clinical isolates) were used in the accumulation experiments.

The tryptone soy agar (TSA), tryptone soy broth (TSB), and Mueller-Hinton broth (MHB) used to culture the strains were purchased from Sharlau (Sentmenat, Barcelona, Spain).

Chemicals {#S0002-S2002}
---------

Colistin was kindly supplied by Zhejiang Shenghua Biok Biology Co., Ltd., (Shanghai, China), Chloramphenicol, amikacin, tetracycline, linezolid, acridine orange, the efflux pump inhibitor phenyl-arginyl-β-naphthylamide (PaβN), used in the accumulation assays, and the fluorescent probes diphenylhexatriene (DPH) and 1-\[4-trimethylamino-phenyl\]-6-phenyl-1,3,5-hexatriene (TMA-DPH) were purchased from Sigma-Aldrich Chemicals (Madrid, Spain). The LIVE/DEAD^®^ BacLight^™^ bacterial viability kit was from Life Technologies (Oregon, USA).

Intracellular accumulation of acridine orange {#S0002-S2003}
---------------------------------------------

Acridine orange (AO: N,N,N',N'-tetramethylacridine-3,6-diamine) produces fluorescence after it penetrates the bacterium and binds to its DNA. It is pumped out from bacterial cells by at least one efflux pump, as shown in *E. coli*[@CIT0017] and other Gram-negative bacteria[@CIT0018] In this study, AO uptake was determined: i) under standard culture conditions, ii) in the presence of the efflux pump inhibitor PaβN[@CIT0019] (20 µg/ml), and iii) in the presence of sub-inhibitory concentrations of colistin (0.25 and 0.125 µg/ml).

The assays were performed in flat-bottomed microtiter plates, with the same plate used for the three different conditions. Each well contained 100 µl of the bacterial inoculun and 100 µl of medium. Overnight cultures were diluted in Ringer's solution to an optical density (OD) of 1.5 at 520 nm. The inoculated plates were incubated for 1 h, after which fluorescence was measured in a FLUOstar OPTIMA Biogen fluorescent microplate reader. The results were expressed as the percentage increase in fluorescence vs that in wells containing bacteria and AO (=100%).

Susceptibility test {#S0002-S2004}
-------------------

The microdilution method was used to determine the minimum inhibitory concentrations (MICs) of colistin, chloramphenicol, tetracycline, vancomycin, and linezolid in each of the strains, according to EUCAST recommendations. Susceptibility was defined following EUCAST definition of antimicrobial breakpoints[@CIT0020] The MIC was also determined in the presence of the efflux pump inhibitor PaβN. Bacterial susceptibility to several different antimicrobials (chloramphenicol, tetracycline, vancomycin, and linezolid) in the presence of sub-inhibitory concentrations of colistin was evaluated as well.

Fluorescent live/dead testing {#S0002-S2005}
-----------------------------

To rule out bacterial death during the accumulation experiment and to show that AO fluorescence was due solely to an increase in the uptake of the dye, the viability of the bacteria in the presence of different concentrations of colistin was determined in a live-dead analysis.

Briefly, 1 ml of bacterial suspension (prepared as described above for the AO accumulation experiment) was incubated with colistin and centrifuged for 5 min at 18,000×g and then stained with 100 µl of the Live/Dead kit solution (LIVE/DEAD^®^ BacLight^™^). The cells were subsequently examined by confocal laser scanning microscopy (CLSM) using a ZEISS LSM 880 microscope equipped with a 488 nm argon laser, 561 nm and 633 nm diode lasers, and a 63× magnification oil immersion objective. All experiments were performed in duplicate. CLSM images were analyzed using the ZEN 2.3 software. The proportions of living vs dead bacteria were calculated.

Membrane polarization and anisotropy {#S0002-S2006}
------------------------------------

Bacterial cultures with or without colistin were washed twice in buffer and then suspended in saline buffer to a final OD~500~ of 0.4. After the addition of DPH or TMA-DPH to a final concentration of 2 μM and 1 μM, respectively, the cultures were incubated for 15 min at 37 ºC to enhance incorporation of the probes into the bacterial membranes. Anisotropy measurements were performed in cells incubated for 1 h in the presence of colistin.

Fluorescence was measured using a SLM-Aminco 8100 spectrofluorometer with a thermal jacketed cuvette holder. Fluorescence anisotropy (*r*) was calculated as: $$\documentclass[12pt]{minimal}
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where *I*~ij~ is the fluorescence intensity measured when the excitation (*i*) and emission (*j*) polarizers are fixed in the vertical (*V*) or horizontal (*H*) position and *G* is the ratio of the sensitivities of the detection system for vertically and horizontally polarized light. Samples fluorescence emission was measured at 37 °C using excitation and emission wavelengths of 381 nm and 426 nm, respectively[@CIT0021]

Results {#S0003}
=======

Susceptibility testing {#S0003-S2001}
----------------------

The MICs for the antimicrobials investigated in this study are shown in [Table 1](#T0001){ref-type="table"}. All tested strains were susceptible to colistin according to the breakpoint defined by EUCAST. [Table 1](#T0001){ref-type="table"} also shows the effect of sub-inhibitory concentrations of colistin on the MICs of other antimicrobials. The activities of all antimicrobials tested increased when used in combination with colistin at ½ of its MIC. The greatest reduction in the MICs of these drugs was obtained in *A. baumannii*, with moderate reductions determined in *P. aeruginosa* and *E. coli*. No significant deviations were measured in the different series of experiments.Table 1Bacterial susceptibility to antimicrobials administered either alone or in combination with colistin at ½ its MIC*Acinetobacter baumannii*COLCHLCHL+COLTETTET+COLLZDLZD+COLVANVAN+COL**ABAU 137**164≤0.125\>1281\>2564\>2561**ABAU 80**1640.5\>1281\>25682562**ABAU 226**11280.541\>25616\>2568**ATCC 17978**1640.520.25\>256162564**ABAU 8**164≤0.125\>1280.5\>256162561**ABAU RUH-875**1\>1280.25320.5\>25681284**ABAU 176**11280.5\>1281\>256162568**ABAU 34**0.5640.5\>1282\>25616\>2562***Pseudomonas aeruginosa*PA 362**0.2564442\>256642562**PA 350**0.58484256321282**PA 056**0.5642164\>25632\>2568**PA 846**0.258440.5128161288**PA O1**0.516284\>2563212816**PA 023**0.580.25162\>25664\>2568**PA 666**11282162\>2563212816**PA 086**0.580.581\>2566425616**ATCC 27853**0.56441281\>256642568***Escherichia coli.*MDR 211453**0.54411256322568**MDR 39255**0.54112864256322568**MDR 208691**0.5\>1282\>12832256322568**MDR 205119**0.5641\>128161281612816**MDR 246415**1\>12816\>1282256321288**MDR 239910**116212816256162568**MDR 238192**0.512832\>128322561625616**MDR 215482**1\>12864\>12816\>2568\>2564**MDR 213873**14412816128646416**ATCC 25922**0.51110,251281612816[^1][^2]

Acridine orange accumulation {#S0003-S2002}
----------------------------

Acridine orange penetrates Gram-negative bacteria easily, although it is normally expelled by efflux pumps located in the bacterial membrane[@CIT0022] However, as shown in [Figure 1A](#F0001){ref-type="fig"}--[C](#F0001){ref-type="fig"}, in the presence of PaβN, an efflux pump inhibitor, the uptake of AO increased by nearly 200% in *E. coli* and by \~170% in *P. aeruginosa* and *A. baumannii*. Similar effects were achieved with sub-inhibitory concentrations of colistin (0.25 µg/ml), which increased AO uptake in *E. coli* by \~160%, in *P. aeruginosa* by 140%, and in *A. baumannii* by \>125%. The accumulation of AO was concentration-dependent, at least at the colistin concentrations tested (0.125 and 0.25 µg/ml). Moreover, low concentrations of colistin also increased AO accumulation by S*erratia marcescens*, a bacterium intrinsically resistant to colistin ([Figure 1D](#F0001){ref-type="fig"}). Accumulation values obtained were highly repetitive. In [Figure 1](#F0001){ref-type="fig"} standard deviations are represented.Figure 1Average acridine orange (AO) accumulation in the presence of the efflux inhibitor PaβN and sub-inhibitory concentrations of colistin. (**A**--**C**) colistin-sensitive strains; (**D**) a species intrinsically resistant to colistin.

To rule out that these results reflected differences in bacterial viability, a live/dead assay was conducted and the results were evaluated by CLSM ([Figure 2](#F0002){ref-type="fig"}). Bacterial death in the presence of colistin was \~6%, the same as in the control (without colistin). Thus, at the tested sub-inhibitory concentrations, the membrane effects of colistin did not cause a reduction in cell viability. In addition, propidium iodide was unable to penetrate the colistin-treated bacteria.Figure 2Confocal light microscopy imaging after Live/Dead staining of *Pseudomonas aeruginosa*. (**A**) Untreated cells; (**B**) cells treated with colistin at 0.25 μg/mL and (**C**) cells treated with colistin at bactericidal concentration. Similar images were obtained for *Acinetobacter baumanii* and *E. coli* (not shown). TEM of thin sections of *S. marcescens* after treatment with colistin. Blebs formed by the outer membrane are easily visualized.

Membrane polarization {#S0003-S2003}
---------------------

Anisotropy is the inverse of microviscosity. It can be measured in membranes using the hydrophobic probe DPH, which enters the inner domain of the lipid bilayer and becomes lodged parallel to the hydrocarbon chain axis of the phospholipids but also in the centre of the bilayer, parallel to the surface. Trimethylammonium (TMA)-DPH, the cationic derivative of DPH, localizes closer to the external surface of the lipid membrane, as the cationic TMA substituent acts as a surface anchor. [Table 2](#T0002){ref-type="table"} shows the DPH- and TMA-DPH-based anisotropy values in the three tested species of bacteria incubated with 2 and 0.25 µg colistin/ml. In *E. coli* MDR208691, a 1 h incubation with colistin reduced membrane anisotropy, while in *P.aeruginosa* and *A. baumannii* the reductions were lower (see DPH results in [Table 2](#T0002){ref-type="table"}). Using the TMA_DPH probe, subtle effects of colistin on the membrane of *E. coli* and *P. aeruginosa* were seen, while in *A. baumannii* colistin slightly rigidified the surface of the lipid membrane.Table 2Changes in membrane fluidity (anisotropy) in the presence of colistinColistin (μg/ml)Anisotropy (*r*)DPHTMA-DPH***E. coli***00.2787±0.02190.267±0.0390.250.26986±0.0200.265±0.0282.000.2488±0.0090.2681±0.0212***P. aeruginosa***00.3139±0.0340.284±0.02470.250.3105±0.03590.274±0.01992.000.2877±0.02130.273±0.0212***A. baumannii***00.314±0.0270.255±0.0050.250.306±0.0290.260±0.00812.000.307±0.00250.260±0.006

Discussion {#S0004}
==========

Although the toxicity of colistin resulted in the eventual discontinuation of its use as an antibiotic, with the emergence of bacterial multi-resistance the drug has been resurrected for the treatment of infections by MDR bacteria. However, the re-introduction of colistin has been accompanied by the appearance of resistance to colistin and other polymyxins, most commonly via LPS modification. A further challenge is the heteroresistance of bacterial populations; that is, the presence of resistant subpopulations within an isolate considered susceptible.[@CIT0006],[@CIT0007]

To avoid the development of colistin resistance, the colistin is used in combination with a second antimicrobial agent, based on the advantage conferred by the main mechanism of colistin action: membrane permeabilization. Ritcher et al[@CIT0023] described the increased accumulation of several antimicrobials in the presence of high concentrations of colistin (6 mM =7 µg/ml). In our study, sub-MIC concentrations of colistin were used to explore their ability to enhance the action of other antibiotics while minimizing the risk posed by colistin toxicity. The results showed that sub-MIC concentrations of colistin altered the efflux pump function of the bacterial cells, as evidenced by the increases in AO accumulation in isolates of *E. coli, A. baumannii*, and *P. aeruginosa*. All the three species are naturally susceptible to colistin, which at concentrations at or above its MIC causes catastrophic effects on the outer membrane. Moreover, similar results were obtained in *S. marcescens*, a Gram-negative species that is naturally colistin-resistant. Specifically, we were able to demonstrate severe alterations in AO efflux in *S. marcescens* cells treated with sub-inhibitory concentrations of colistin. This result suggests a mechanism of outer membrane injury in Gram-negative bacteria in which correct formation of the AcrAB-tolC complex and other efflux-pump-based complexes is prevented and efflux is therefore interrupted.

Diffusion and active transport by efflux systems are strongly dependent on membrane fluidity[@CIT0024] Vincent et al[@CIT0025] described changes in membrane polarization in bacterial cells exposed to tetracycline. As the main mechanism of action of colistin is membrane disruption, we hypothesized that concentrations of the drug below the MIC would be sufficient to alter membrane fluidity. Our results showed that low concentrations of colistin significantly increased the fluidity of the inner regions of the lipid bilayers without significantly modifying the more polar regions of the membrane, as indicated by anisotropy measurements. These colistin-induced membrane alterations would presumably i) facilitate the penetration of other antimicrobials and thus increase their biological activity and ii) decrease the lateral lipid pressure inside lipid membranes to reduce local rigidity and modify the correct packing of the efflux pumps, thus altering the efflux of drugs reaching the cell, as observed in [Figure 1](#F0001){ref-type="fig"}.

Using a live/dead assay, we showed that, at 1/2 its MIC, colistin did not cause bacterial death or injury to the cytoplasmic membrane, as the amount of propidium iodide and thus the proportion of living bacteria were identical in colistin-treated and untreated (control) cells. Therefore, the above-described results cannot be explained by differences in bacterial viability.

The cellular accumulation of AO increases in the presence of the efflux pump inhibitor PaβN since the dye is normally pumped out by efflux systems. Sub-inhibitory concentrations of colistin also led to increases in the amount of AO retained by the bacteria. Given the results of the live/dead test, the observed accumulation of AO can be attributed to the disruption of membrane permeability by colistin and to the indirect inhibition of the cellular efflux machinery.

We then demonstrated that sub-inhibitory concentrations of colistin increase the activity of antimicrobials whose mechanisms of resistance are associated with efflux systems and/or decreased permeability ([Table 1](#T0001){ref-type="table"}). The synergy between clinically relevant concentrations of colistin and chloramphenicol in *Klebsiella pneumoniae*[@CIT0016] as well as between colistin and colistin-like peptides and carbapenems in imipenem-resistant *P. aeruginosa*[@CIT0015] has been reported. An enhancement of the activity of glycopeptides targeting *A. baumannii* was also shown in vivo, in the moth *Galleria mellonella*, in which colistin increased the antimicrobial activity of vancomycin by up to 90%.[@CIT0014],[@CIT0026] Moreover, Liu et al[@CIT0013] reported the efficacy of anti-Gram-positive antimicrobials in the treatment of *A. baumannii* infections when these drugs were administered together with colistin. During the writing of the present article, Brennan-Krohn et al[@CIT0027] published a study demonstrating the synergism of colistin and a wide range of antimicrobials in both colistin-susceptible and colistin-resistant Enterobacteriaceae. The authors attributed these results to the direct effect of colistin on the bacterial outer membrane. Almost simultaneously, Fang et al[@CIT0028] reported similar data in tests of *E. coli* exposed to combinations of colistin and either azithromycin or rifampin, both in vitro and in vivo. Our data provide additional, biophysical evidence supporting those observations. Furthermore, these results together suggest lines of further research aimed at the development of compounds that, while unable to kill bacteria themselves, significantly alter bacterial membrane fluidity and thus potentiate the activity of traditional antimicrobials.

In summary, our study showed that, by altering the permeability of the outer membrane of Gram-negative bacteria, colistin acts synergistically with a broad spectrum of antimicrobials. The mechanism of action involves modification of membrane fluidity as well as the direct partial inhibition of efflux pump function.
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[^1]: **Note:** MICs are reported in µg/ml.

[^2]: **Abbreviations:** COL, colistin; CHL, chloramphenicol; TET, tetracycline; LZD, linezolid; VAN, vancomycin.
